ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Growth Strategy” fourth ...

U.S.-listed shares of Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) are up 3.5% premarket, following a bull note ...

Novo Nordisk (NVO) and Valo Health expand collaboration to develop new treatments targeting cardiometabolic diseases. Read ...

Fintel reports that on January 5, 2025, BNP PARIBAS EXANE upgraded their outlook for Novo Nordisk A (NYSE:NVO) from Neutral ...

UBS analyst upgraded Novo Nordisk (NVO) to Buy from Neutral with a price target of DKK 750, down from DKK 1,100. Novo Nordisk is “well placed” ...

In the closing of the recent trading day, Novo Nordisk (NVO) stood at $83.34, denoting a -1.99% change from the preceding trading day.

Under the expanded collaboration, Valo's Opal Computational Platform will be integrated with Novo Nordisk's expertise in cardiometabolic diseases, deriving insights from real-world patient data, ...

JMP Securities analyst Ronald Josey maintained Lemonade with a Market Outperform and raised the price target from $40 to $60.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo Nordisk said an agreement reached last year with privately held Lexington, Mass. company Valo Health that initially was valued at up to $2.7 billion is now been expanded to a $4.6 billion deal.

Novo Nordisk A/S (NYSE:NVO – Get Free Report) was upgraded by equities researchers at Sanford C. Bernstein from an “underperform” rating to a “market perform” rating in a research note issued on ...

COPENHAGEN (Reuters) - Greenland's leader was expected to hold talks on Wednesday with the Danish king in Copenhagen, after U ...